• 1
    Murphy GF. Cutaneous T cell lymphoma. Adv Pathol. 1988; 1: 131156.
  • 2
    Bunn PA Jr., Lamberg SI. Report of the committee on staging and classification of cutaneous t-cell lymphomas. Cancer Treat Rep. 1979; 63: 725728.
  • 3
    Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol. 1999; 26: 276289.
  • 4
    Willemze R, Meijer CJLM. EORTC classification for primary cutaneous lymphoma: a comparison with the R.E.A.L. classification and the proposed WHO classification. Ann Oncol. 2000; 11: S11S15.
  • 5
    Willemze R, Meijer CJLM. Classification of cutaneous lymphomas: cross-talk between pathologist and clinician. Curr Diagn Pathol. 1998; 5: 2333.
  • 6
    Barcos M. Mycosis fungoides. Diagnosis and pathogenesis. Haematopathology. 1992; 30: 452457.
  • 7
    Toro JR, Stoll H Jr. Oseroff AR. Prognostic factors and evaluation of mycosis fungoides and Sésary syndrome. J Am Acad Dermatol. 1997; 37: 5867.
  • 8
    Kemme DJ, Bunn PA. State of the art therapy of mycosis fungoides and Sézary syndrome. Oncology. 1992; 6: 3142.
  • 9
    Vonderheid EC, Tan ET, Kantor AF, et al.. Long-term efficacy, curative potential and carcinogenicity of topical mechloretamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989; 20: 416428.
  • 10
    Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Arch Dermatol. 1998; 134: 949954.
  • 11
    Gupta AK, Anderson TF. Psolaren photochemotherapy. J Am Acad Dermatol. 1987; 17: 703734.
  • 12
    Roenigk HH Jr., Kuzel TM, Skoutelis AP, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990; 95 (Suppl 6): 198S205S.
  • 13
    Van Vloten WA, Vroome H, Noordijk EM. Total skin electron beam irradiation for cutaneous T-cell lymphoma. Br J Dermatol. 1985; 112: 697702.
  • 14
    Quiros PA, Jones GW, Kacinski BM, et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiol Oncol Biol Phys. 1997; 38: 10271035.
  • 15
    Armus S, Keyes B, Cahill C, et al. Photopheresis in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1990; 23: 898902.
  • 16
    Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol. 1987; 123: 201204.
  • 17
    Knobler RM, Trautinger F, Radaszkiewicz T, et al. Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol. 1991; 24: 247252.
  • 18
    O'Brien S, Kurzrock R, Duvie M, et al. 2-Clorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994; 84: 733738.
  • 19
    Von Hoff D, Dahlberg S, Harstock R, et al. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Natl Cancer Inst. 1990; 82: 13531355.
  • 20
    Hesketh P, Caguioa P, Koh H, et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 1993; 11: 16821696.
  • 21
    Bunn PA Jr., Ihde DC, Foon KA. The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphomas. Cancer. 1986; 57: 16891695.
  • 22
    Bunn PA Jr., Foon KA, Ihde DC, et al. Recombinant leucocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med. 1984; 101: 484487.
  • 23
    Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol. 1993; 51: 6372.
  • 24
    Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995; 9: 10891107.
  • 25
    Kuzel TM, Gilyon K, Springer E, et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990; 82: 203207.
  • 26
    Mostow EN, Nechel SL, Oberherlman L, et al. Complete remissions in psolaren and UVA (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol. 1993; 129: 747752.
  • 27
    Kuzel TM, Roenigk HH, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol. 1995; 13: 257263.
  • 28
    Roenigk HH, Kuzel TM, Skoutelis AP, et al. Photochemotherapy alone or combined with interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990; 95: 198S205S.
  • 29
    Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon α-2a plus acitretin versus interferon-α-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1992; 10: 35783581.
  • 30
    Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med. 1987; 316: 297303.
  • 31
    Sieghel R, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphomas: review and current concepts. J Clin Oncol. 2000; 18: 29082925.
  • 32
    Kaye FJ, Bunn PA Jr., Steinberg SM. A randomized trial comparing combination electronic-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989; 321: 17841790.
  • 33
    Muche M, Lukowsky A, Asadullah K, et al. Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood. 1997; 4: 16361642.
  • 34
    Gottlied SL, Wolfe JT, Floyd EF, et al: Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol. 1996; 35: 946957.